Pub. Date : 2018 Dec 21
PMID : 30577630
9 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | The current studies determined the functional significance of PAF-R in gemcitabine chemotherapy-mediated MVP release in human pancreatic cancer cells. | gemcitabine | platelet activating factor receptor | Homo sapiens |
| 2 | Using PAF-R-expressing (PANC-1) and PAF-R-deficient (Hs766T) cells, we demonstrate that gemcitabine induces MVP release in a PAF-R-dependent manner. | gemcitabine | platelet activating factor receptor | Homo sapiens |
| 3 | Using PAF-R-expressing (PANC-1) and PAF-R-deficient (Hs766T) cells, we demonstrate that gemcitabine induces MVP release in a PAF-R-dependent manner. | gemcitabine | platelet activating factor receptor | Homo sapiens |
| 4 | Using PAF-R-expressing (PANC-1) and PAF-R-deficient (Hs766T) cells, we demonstrate that gemcitabine induces MVP release in a PAF-R-dependent manner. | gemcitabine | platelet activating factor receptor | Homo sapiens |
| 5 | Blocking of PAF-R via PAF-R antagonist or inhibition of MVP generation via inhibitor of acid sphingomyelinase (aSMase) enzyme, significantly attenuated gemcitabine-mediated MVP release from PANC-1 cells, however, exerted no effects in Hs766T cells. | gemcitabine | platelet activating factor receptor | Homo sapiens |
| 6 | Mechanistically, pretreatment with ERK1/2 or p38 inhibitors significantly abrogated gemcitabine-mediated MVP release, indicating the involvement of mitogen-activated protein kinase (MAPK) pathway in PAF-R-dependent gemcitabine-mediated MVP release. | gemcitabine | platelet activating factor receptor | Homo sapiens |
| 7 | Mechanistically, pretreatment with ERK1/2 or p38 inhibitors significantly abrogated gemcitabine-mediated MVP release, indicating the involvement of mitogen-activated protein kinase (MAPK) pathway in PAF-R-dependent gemcitabine-mediated MVP release. | gemcitabine | platelet activating factor receptor | Homo sapiens |
| 8 | These findings demonstrate the significance of PAF-R in gemcitabine-mediated MVP release, as well as the rationale of evaluating PAF-R targeting agents with gemcitabine against pancreatic cancer. | gemcitabine | platelet activating factor receptor | Homo sapiens |
| 9 | These findings demonstrate the significance of PAF-R in gemcitabine-mediated MVP release, as well as the rationale of evaluating PAF-R targeting agents with gemcitabine against pancreatic cancer. | gemcitabine | platelet activating factor receptor | Homo sapiens |